IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: PLATCHER

Sergel No.: 10,770,467

Filed: February 4, 2004

For: Viral Particles Which Are Released After

the Infection With the Human

Cytomegalovirus and the Use of Said

Particles as a Vaccine

Art Unit: 1648

Examiner:

Humphrey, Louise Wang Zhiying

Atty. Docket: 966927-10001

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:


Listed on the accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that an exhaustive search has been made, or that there does not exist information more material to the examination of the present patent application. The Examiner is specifically requested not

to rely solely on the material submitted herewith. It is further understood that the Examiner will review art of record in all 35 U.S.C. § 120 priority documents.

		,
□1.	This Information Disclosure Statement is being filed within three months of the U.S. filing date	
	OR before the mailing date of a first Office Action on the merits. No certification or fee is	
	required.	
□2.	The Information Disclosure Statement is being filed more than three months after the U.S. filing	
	date AND after the mailing date of the first Office Action on the merits, but before the mailing	
	date of a Final Rejection or Notice of Allowance.	
	□а.	I hereby certify that each item of information contained in this Information Disclosure
		Statement was cited in a communication from a foreign patent office in a counterpart
		foreign application not more than three months prior to the filing of this Information
		Disclosure Statement. 37 C.F.R. § 1.97(e)(1).
	□ b.	I hereby certify that no item of information in this Information Disclosure Statement was
		cited in a communication from a foreign patent office in a counterpart foreign application
		or, to my knowledge after making reasonable inquiry, was known to any individual
		designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this
		Information Disclosure Statement. 37 C.F.R. § 1.97(e)(2).
	□ c.	Attached is our check no in the amount of \$180.00 in payment of the fee under
		37 C.F.R. § 1.17(p).
3. This Informa		formation Disclosure Statement is being filed more than three months after the U.S. filing
	date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of	
	the Issue Fee. Applicants hereby petition that the Information Disclosure Statement be	
	considered. Attached is our check no in the amount of \$130.00 in payment of the	
	fee under 37 C.F.R. § 1.17(i)(1).	
	□ a.	I hereby certify that each item of information contained in this Information Disclosure



It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 50-0622.

Respectfully submitted,

REED SMITH LLP

Chris Aniedobe

Reg. No. 48,293

Date:

3110 Fairview Park Drive

Suite 1400

Falls Church, VA 22042

703-641-4200